Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a persistent or long-standing persistent form of atrial fibrillation (an irregular heartbeat that does not come and go but stays ongoing)
- People who already need non-emergency open-heart surgery for another reason, such as a heart bypass operation or heart valve repair or replacement
- People who are able to take blood-thinning medication, either warfarin or one of the newer types of blood thinners known as NOACs
Who may not be able to join:
- People who have a heart condition called Wolff-Parkinson-White syndrome
- People whose heart failure has been classified as the most severe level (Class IV) by their doctor
- People whose heart pumping strength (left ventricular ejection fraction) is at or below 30%
- People who need emergency heart surgery, such as for cardiogenic shock (when the heart suddenly cannot pump enough blood), or who have already had open-heart surgery before
- People who have previously had a procedure to treat their atrial fibrillation, including catheter ablation, AV-node ablation, or a surgical Maze procedure
- People who are unable to take blood-thinning medication for medical reasons
- People whose left atrial chamber (one of the heart's upper chambers) measures more than 6.0 cm
- People who need a heart-assist balloon pump or strong heart medications given through a drip before surgery
- People who have kidney failure requiring dialysis, or serious liver failure
- People whose life expectancy is estimated to be less than one year
- People whose estimated risk of not surviving the operation is greater than 10%, based on a standard surgical risk calculator
- People who are pregnant or plan to become pregnant within 12 months of the study treatment
- People who currently have an active infection anywhere in the body
- People who currently have an active infection of the heart valves (endocarditis)
- People who had a heart attack in the 30 days before enrolling in the study
- People who are currently taking part in, or planning to join, another trial or observational study involving a drug or device for treating heart rhythm problems
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ralph J Damiano, MD, Washington University School of Medicine
Phone: 763-526-2032
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite acute major adverse event rate; Freedom from Atrial Fibrillation (AF)/Atrial Flutter (AFL)/Atrial Tachycardia (AT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.